{"id":"glutamic-acid","rwe":[{"pmid":"41905693","year":"2026","title":"Supplementation of glucomannans ameliorate high-fat diet-induced cognitive impairment via a gut microbiota-metabolite-glutamatergic synapse axis.","finding":"","journal":"International journal of biological macromolecules","studyType":"Clinical Study"},{"pmid":"41905412","year":"2026","title":"Islet autoantibody profiles at diagnosis of childhood type 1 Diabetes: Age-Dependent heterogeneity and clinical implications.","finding":"","journal":"Diabetes research and clinical practice","studyType":"Clinical Study"},{"pmid":"41903387","year":"2026","title":"Instrument-free quantitative colorimetric analysis using adsorption-band length in a packed silica gel column.","finding":"","journal":"Talanta","studyType":"Clinical Study"},{"pmid":"41902580","year":"2026","title":"\"Steak Dry Aging\": An Innovative Approach to Producing High-Yield, High-Quality Dry-Aged Beef.","finding":"","journal":"Journal of food science","studyType":"Clinical Study"},{"pmid":"41900040","year":"2026","title":"Chemical and Rheological Modifications of White Sorghum Flour by Physical Treatments with Possible Implications for Health.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"}],"_fda":{"id":"488d78ac-3cd2-4593-8968-2992fe59bb49","set_id":"2d212e10-7e08-4aeb-b63f-dcc927897769","openfda":{"nui":["N0000175780","M0000922"],"unii":["OF5P57N2ZX","94ZLA3W45F","30KYC7MIAI","3KX376GY7L","TE7660XO1C","4QD397987E","04Y7590D77","GMW67QNF9C","TTL6G7LIWZ","AE28F7PNPL","47E5O17Y3R","9DLQ4CIU6V","452VLY9402","1EQV5MLY3D","2ZD004190S","8DUH1N11BX","42HK56048U","HG18B9YRS7"],"route":["INTRAVENOUS"],"rxcui":["831426","831430"],"spl_id":["488d78ac-3cd2-4593-8968-2992fe59bb49"],"brand_name":["Aminosyn-PF"],"spl_set_id":["2d212e10-7e08-4aeb-b63f-dcc927897769"],"package_ndc":["0990-4178-03"],"product_ndc":["0990-4178"],"generic_name":["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Amino Acids [CS]"],"substance_name":["ALANINE","ARGININE","ASPARTIC ACID","GLUTAMIC ACID","GLYCINE","HISTIDINE","ISOLEUCINE","LEUCINE","LYSINE ACETATE","METHIONINE","PHENYLALANINE","PROLINE","SERINE","TAURINE","THREONINE","TRYPTOPHAN","TYROSINE","VALINE"],"pharm_class_epc":["Amino Acid [EPC]"],"manufacturer_name":["ICU Medical Inc."],"application_number":["NDA019398"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Safe, effective use of parenteral nutrition requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of the complications which can occur. FREQUENT EVALUATION AND LABORATORY DETERMINATIONS ARE NECESSARY FOR PROPER MONITORING OF PARENTERAL NUTRITION. Studies should include blood sugar, serum proteins, kidney and liver function tests, electrolytes, hemogram, carbon dioxide content, serum osmolalities, blood cultures, and blood ammonia levels. Administration of amino acids in the presence of impaired renal function or gastrointestinal bleeding may augment an already elevated blood urea nitrogen. Patients with azotemia from any cause should not be infused with amino acids without regard to total nitrogen intake. Administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the solutions. Administration of amino acid solutions to a patient with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Hyperammonemia is of special significance in infants , as its occurrence in the syndrome caused by genetic metabolic defects is sometimes associated, although not necessarily in a causal relationship, with mental retardation. This reaction appears to be dose-related and is more likely to develop during prolonged therapy. It is essential that blood ammonia be measured frequently in infants. Conservative doses of amino acids should be given, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid dosage levels should be reduced and titrated against serum ammonia levels. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"pregnancy":["Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS ."],"description":["DESCRIPTION Aminosyn ® -PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is a sterile, nonpyrogenic solution for intravenous infusion. Aminosyn ® -PF 7% is oxygen sensitive. The formulation is described below: Aminosyn-PF 7% An Amino Acid Injection — Pediatric Formula Essential Amino Acids (mg/100 mL) Isoleucine 534 Leucine 831 Lysine (acetate)* 475 Methionine 125 Phenylalanine 300 Threonine 360 Tryptophan 125 Valine 452 * Amount cited is for lysine alone and does not include the acetate salt. Nonessential Amino Acids (mg/100 mL) Alanine 490 Arginine 861 L-Aspartic Acid 370 L-Glutamic Acid 576 Glycine 270 Histidine 220 Proline 570 Serine 347 Taurine 50 Tyrosine 44 Electrolytes (mEq/L) Sodium (Na + ) (mEq/L) None Potassium (K + ) (mEq/L) None Chloride (Clˉ) (mEq/L) None Acetate (C 2 H 3 O 2 ˉ) a (mEq/L) 32.5 a From lysine acetate. Product Characteristics Protein Equivalent (Approx. grams/L) 70 Total Nitrogen (grams/L) 10.69 Osmolarity (mOsmol/L) 561 pH (range) 5.5 (5.0 to 6.5) The formulas for the individual amino acids present in Aminosyn-PF 7% are as follows: Essential Amino Acids Isoleucine, USP C 6 H 13 NO 2 Leucine, USP C 6 H 13 NO 2 Lysine Acetate, USP C 6 H 14 N 2 O 2 • CH 3 COOH Methionine, USP C 5 H 11 NO 2 S Phenylalanine, USP C 9 H 11 NO 2 Threonine, USP C 4 H 9 NO 3 Tryptophan, USP C 11 H 12 N 2 O 2 Valine, USP C 5 H 11 NO 2 Nonessential Amino Acids Alanine, USP C 3 H 7 NO 2 Glycine, USP C 2 H 5 NO 2 Arginine, USP C 6 H 14 N 4 O 2 L-Aspartic Acid C 4 H 7 NO 4 HO 2 CCH 2 CH(NH 2 )CO 2 H L-Glutamic Acid C 5 H 9 NO 4 HO 2 CCH 2 CHCH(NH 2 )CO 2 H Histidine, USP C 6 H 9 N 3 O 2 Proline, USP C 5 H 9 NO 2 Serine, USP C 3 H 7 NO 3 Taurine C 2 H 7 NO 3 S Tyrosine, USP C 9 H 11 NO 3 The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period."],"precautions":["PRECAUTIONS Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements. Strongly hypertonic nutrient solutions should be administered via an intravenous catheter placed in a central vein, preferably the superior vena cava. Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency. Special care must be taken when giving hypertonic dextrose to a diabetic or pre-diabetic patient. To prevent severe hyperglycemia in such patients, insulin may be required. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma, and death. The effect of infusion of amino acids, without dextrose, upon carbohydrate metabolism of children is not known at this time. It is essential to provide adequate exogenous dextrose calories concurrently with amino acids. Administration of amino acids without carbohydrates may result in the accumulation of ketone bodies in the blood. Correction of this ketonemia may be achieved by the administration of carbohydrate. Essential fatty acid deficiency (EFAD) is becoming increasingly recognized in patients on long term TPN (more than 5 days). The use of fat emulsion to provide 4 — 10% of total caloric intake as linoleic acid may prevent EFAD. Peripheral administration of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) requires appropriate dilution and provision of adequate calories. Care should be taken to assure proper placement of the needle within the lumen of the vein. The venipuncture site should be inspected frequently for signs of infiltration. If venous thrombosis or phlebitis occurs, discontinue infusions or change infusion site and initiate appropriate treatment. Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea, or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. Metabolic acidosis can be prevented or readily controlled by adding a portion of the cations in the electrolyte mixture as acetate salts and in the case of hyperchloremic acidosis, by keeping the total chloride content of the infusate to a minimum. Aminosyn-PF 7% contains no chloride. Aminosyn-PF 7% contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. To assure adequate intake, serum levels should be monitored frequently. Aminosyn-PF 7% contains no more than 25 mcg/L of aluminum. To minimize the risk of possible incompatabilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration. SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS. Central vein infusion (with added concentrated carbohydrate solutions) of amino acid solutions requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of complications. Attention must be given to solution preparation, administration and patient monitoring. IT IS ESSENTIAL THAT A CAREFULLY PREPARED PROTOCOL, BASED ON CURRENT MEDICAL PRACTICES, BE FOLLOWED, PREFERABLY BY AN EXPERIENCED TEAM. SUMMARY HIGHLIGHTS OF COMPLICATIONS (See also Current Medical Literature). 1. Technical The placement of a central venous catheter should be regarded as a surgical procedure. One should be fully acquainted with various techniques of catheter insertion. For details of technique and placement sites, consult the medical literature. X-ray is the best means of verifying catheter placement. Complications known to occur from the placement of central venous catheters are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arteriovenous fistula, phlebitis, thrombosis and air and catheter emboli. 2. Septic The constant risk of sepsis is present during administration of total parenteral nutrition. It is imperative that the preparation of the solution and the placement and care of catheters be accomplished under strict aseptic conditions. Solutions should ideally be prepared in the hospital pharmacy under a laminar flow hood using careful aseptic technique to avoid inadvertent touch contamination. Solutions should be used promptly after mixing. Storage should be under refrigeration and limited to a brief period of time, preferably less than 24 hours. Administration time for a single container and set should never exceed 24 hours. 3. Metabolic The following metabolic complications have been reported with TPN administration: Metabolic acidosis and alkalosis, hypophosphatemia, hypocalcemia, osteoporosis, hyperglycemia and glycosuria, rebound hypoglycemia, osmotic diuresis and dehydration, elevated liver enzymes, hypo- and hypervitaminosis, electrolyte imbalances and hyperammonemia in children. Frequent evaluations are necessary especially during the first few days of therapy to prevent or minimize these complications. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma and death. CLINICAL EVALUATION AND LABORATORY DETERMINATIONS, AT THE DISCRETION OF THE ATTENDING PHYSICIAN ARE NECESSARY FOR PROPER MONITORING DURING ADMINISTRATION. Do not withdraw venous blood for blood chemistries through the peripheral infusion site, as interference with estimations of nitrogen-containing substances may occur. Blood studies should include glucose, urea nitrogen, serum electrolytes, ammonia, cholesterol, acid-base balance, serum proteins, kidney and liver function tests, osmolarity and hemogram. White blood count and blood cultures are to be determined if indicated. Urinary osmolality and glucose should be determined as necessary. Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"how_supplied":["HOW SUPPLIED NDC No. Concentration Container (mL) 0409-4178-03 Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection - 500 0990-4178-03 pediatric formula) ICU Medical is transitioning NDC codes from the \"0409\" to a \"0990\" labeler code. Both NDC codes are expected to be in the market for a period of time. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.] Protect from freezing. Avoid exposure to light. Revised: August, 2018 EN-4682 ICU Medical, Inc., Lake Forest, Illinois, 60045 USA"],"effective_time":"20251017","adverse_reactions":["ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be injected at another venous site. Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary."],"contraindications":["CONTRAINDICATIONS Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism (including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia), or hypersensitivity to one or more amino acids present in the solution."],"description_table":["
Aminosyn-PF 7%An Amino Acid Injection — Pediatric Formula
Essential Amino Acids (mg/100 mL)
Isoleucine534
Leucine831
Lysine (acetate)*475
Methionine125
Phenylalanine300
Threonine360
Tryptophan125
Valine452
","
Nonessential Amino Acids (mg/100 mL)
Alanine490
Arginine861
L-Aspartic Acid370
L-Glutamic Acid576
Glycine270
Histidine220
Proline570
Serine347
Taurine50
Tyrosine44
","
Electrolytes (mEq/L)
Sodium (Na+) (mEq/L)None
Potassium (K+) (mEq/L)None
Chloride (Clˉ) (mEq/L)None
Acetate (C2H3O2ˉ)a (mEq/L)32.5
","
Product Characteristics
Protein Equivalent (Approx. grams/L)70
Total Nitrogen (grams/L)10.69
Osmolarity (mOsmol/L)561
pH (range)5.5 (5.0 to 6.5)
","
Essential Amino Acids
Isoleucine, USPC6H13NO2
Leucine, USPC6H13NO2
Lysine Acetate, USPC6H14N2O2 • CH3COOH
Methionine, USPC5H11NO2S
Phenylalanine, USPC9H11NO2
Threonine, USPC4H9NO3
Tryptophan, USPC11H12N2O2
Valine, USPC5H11NO2
","
Nonessential Amino Acids
Alanine, USPC3H7NO2
Glycine, USPC2H5NO2
Arginine, USPC6H14N4O2
L-Aspartic AcidC4H7NO4
HO2CCH2CH(NH2)CO2H
L-Glutamic AcidC5H9NO4
HO2CCH2CHCH(NH2)CO2H
Histidine, USPC6H9N3O2
Proline, USPC5H9NO2
Serine, USPC3H7NO3
TaurineC2H7NO3S
Tyrosine, USPC9H11NO3
"],"precautions_table":["
SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS
ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS.
"],"how_supplied_table":["
NDC No.ConcentrationContainer (mL)
0409-4178-03Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection -500
0990-4178-03pediatric formula)
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Aminosyn-PF 7% Sulfite-Free, (an amino acid injection — pediatric formula) contains a mixture of essential and nonessential amino acids as well as taurine. The amino acid composition has been specifically formulated to provide a well-tolerated nitrogen source for nutritional support and therapy for infants and young children. When administered in conjunction with a cysteine hydrochloride additive, Aminosyn-PF 7% results in plasma amino acid concentrations approximating a profile consistent with that of a breast-fed infant. The rationale for Aminosyn-PF 7% is based on the observation of inadequate levels of essential amino acids in the plasma of infants receiving total parenteral nutrition (TPN) using conventional amino acid solutions. Clinical studies in infants who required TPN therapy showed that infusion of Aminosyn-PF 7% resulted in plasma amino acid concentrations approximating those of normal breast or formula fed infants. In addition, weight gains, nitrogen balance, and serum protein concentrations were consistent with an improving nutritional status. When infused with hypertonic dextrose as a calorie source, supplemented with cysteine hydrochloride, electrolytes, vitamins, and minerals, Aminosyn-PF 7% provides TPN for infants and young children, with the exception of essential fatty acids. It is thought that the acetate from lysine acetate under the conditions of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available. The amounts of sodium and acetate in Aminosyn-PF 7% are not of clinical significance. The addition of a cysteine hydrochloride additive will contribute to the chloride load. The electrolyte content of any additives that are introduced should be carefully considered and included in input computations. The human newborn conjugates bile with taurine which becomes the primary method of biliary excretion. Taurine deficiency because of its effect on bile salt conjugation and, therefore, on bile salt flow may be of major importance in the genesis of cholestasis. Taurine has also been shown to play a role in central nervous system development."],"indications_and_usage":["INDICATIONS AND USAGE Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with Aminosyn-PF 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. See DOSAGE AND ADMINISTRATION for additional information. Central Venous Infusion Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants or those requiring long-term parenteral nutrition. Peripheral Parenteral Nutrition For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5 to 10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion."],"spl_unclassified_section":["AN AMINO ACID INJECTION - PEDIATRIC FORMULA Flexible Plastic Container Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The total daily dose of the solution depends on the daily protein requirements and on the patient's metabolic and clinical response. Pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram than in the adult. The recommended intravenous dose of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is up to 2.5 g amino acid/kg/day for infants up to 10 kg. For infants and children larger than 10 kg, the total daily dose of amino acids should be up to 25 g amino acids/day for the first 10 kg of body weight plus 1 to 1.25 g amino acid for each kg of body weight over 10 kg. Initial amino acid dosage levels of 1 g/kg/day may be increased gradually in increments of 0.5 g/kg/day to approximate desired intake levels. Aminosyn-PF 7% should be diluted with dextrose prior to use. Nonprotein calories should constitute approximately 100 to 130 kcal/kg/day. Part of the nonprotein caloric requirement may be provided as lipid emulsion administered concurrently to provide up to 60% of daily calories at a dose not to exceed 4 g fat/kg/day. Fluid intake for the infant receiving central venous TPN should be approximately 125 mL/kg/day (range: 100 to 175 mL/kg/day), depending on the clinical condition of the patient. Premature infants with respiratory distress syndrome suspected of having a patent ductus arteriosus should be given fluids more cautiously. Cysteine is considered to be an essential amino acid for infants, especially preterm infants with potentially immature enzyme pathways. Therefore, addition of a cysteine supplement to the TPN admixture is recommended. The intake of cysteine by the preterm infant ingesting maternal milk is approximately 78 mg/kg/day. The suggested intravenous dosage level for Cysteine Hydrochloride Injection, USP is 500 mg (10 mL) for every 12.5 g (179 mL) of Aminosyn-PF 7% administered (see package insert for Cysteine Hydrochloride Injection, USP). In order to avoid potential insolubility of cysteine hydrochloride in admixtures, the foregoing concentration should not be exceeded. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. To prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose solutions are abruptly discontinued. SERUM ELECTROLYTES SHOULD BE MONITORED FREQUENTLY. Electrolytes may be added to the nutrient solution as indicated by the patient's clinical condition and laboratory determinations of plasma values. Major electrolytes are sodium, chloride, potassium, phosphate, magnesium and calcium. Daily administration of intravenous vitamin supplements including a complete complement of fat and water-soluble vitamins is required. Trace metal additives including zinc, copper, manganese, and chromium should also be provided, especially when long-term parenteral therapy is anticipated. Calcium and phosphorus are added to the solution as indicated. Potentially incompatible ions such as calcium and phosphate may be added to alternate infusate bottles to avoid precipitation. In patients with hyperchloremic or other metabolic acidosis, sodium and potassium may be added as the acetate or lactate salts to provide bicarbonate alternates. Bicarbonate should not be administered during infusion of the nutritional solution unless deemed absolutely necessary. Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. To ensure the precise delivery of the small volumes of fluid necessary for total parenteral nutrition in infants, accurately calibrated and reliable infusion systems should be used. Central Venous Nutrition Hypertonic mixtures of amino acids and dextrose may be safely administered by continuous infusion through a central venous catheter with the tip located in the superior vena cava. Initial infusion rates should be slow, and gradually increased to the recommended 60-125 mL per kilogram body weight per day. If administration rate should fall behind schedule, no attempt to \"catch up\" to planned intake should be made. In addition to meeting protein needs, the rate of administration, particularly during the first few days of therapy, is governed by the patient's glucose tolerance. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of glucose levels in blood and urine. Peripheral Parenteral Nutrition For patients in whom the central venous route is not indicated and who can consume adequate calories enterally, Aminosyn-PF 7% may be administered by peripheral vein with parenteral nonprotein calories. The concentration of dextrose in the final admixture is 5 to 10%, and simultaneous administration of lipid emulsion is recommended both as a calorie source and to attenuate the potentially irritating effects of the hypertonic nutritional admixture. Fat emulsion may comprise up to 60% of the daily caloric intake at a dosage level not to exceed 4 g fat/kg/day. It is essential that peripheral infusion be accompanied by adequate caloric intake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. WARNING: Do not use flexible container in series connections."],"spl_product_data_elements":["Aminosyn-PF ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, and TYROSINE ISOLEUCINE ISOLEUCINE LEUCINE LEUCINE LYSINE ACETATE LYSINE METHIONINE METHIONINE PHENYLALANINE PHENYLALANINE THREONINE THREONINE TRYPTOPHAN TRYPTOPHAN VALINE VALINE ALANINE ALANINE ARGININE ARGININE ASPARTIC ACID ASPARTIC ACID GLUTAMIC ACID GLUTAMIC ACID GLYCINE GLYCINE HISTIDINE HISTIDINE PROLINE PROLINE SERINE SERINE TAURINE TAURINE TYROSINE TYROSINE WATER"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 500 mL Bag Label 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION – PEDIATRIC FORMULA EACH 100 mL CONTAINS: TOTAL AMINO ACIDS APPROX. 7 g. ESSENTIAL AMINO ACIDS/100 mL : ISOLEUCINE 534 mg; LEUCINE 831 mg; LYSINE (AS ACETATE SALT) 475 mg; METHIONINE 125 mg; PHENYLALANINE 300 mg; THREONINE 360 mg; TRYPTOPHAN 125 mg; VALINE 452 mg. NONESSENTIAL AMINO ACIDS/100 mL: TYROSINE 44 mg; ALANINE 490 mg; ARGININE 861 mg; GLYCINE 270 mg; PROLINE 570 mg; HISTIDINE 220 mg; SERINE 347 mg; L-GLUTAMIC ACID 576 mg; L-ASPARTIC ACID 370 mg; TAURINE 50 mg. ELECTROLYTES (mEq/LITER): ACETATE 32.5. pH 5.5 (5.0 to 6.5) 561 mOsmol/LITER SPECIFIC GRAVITY = 1.02 ADDITIVES MAY BE INCOMPATIBLE. CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE. SINGLE DOSE CONTAINER. CONTAINS NO BACTERIOSTAT. DISCARD UNUSED PORTION. FOR I.V. USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC. STORE AT 20 TO 25°C (68 TO 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.] AVOID EXCESSIVE HEAT. PROTECT FROM FREEZING. AVOID EXPOSURE TO LIGHT. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. RX ONLY IM-4405 3 v CONTAINS DEHP icumedical ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Bag Label","PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label TO OPEN – TEAR AT NOTCH 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION — PEDIATRIC FORMULA Each 100 mL contains: Total amino acids approx. 7 g. Essential Amino Acids/100 mL: Isoleucine 534 mg; leucine 831 mg; lysine (as acetate salt) 475 mg; methionine 125 mg; phenylalanine 300 mg; threonine 360 mg; tryptophan 125 mg; valine 452 mg. Nonessential Amino Acids/100 mL: Tyrosine 44 mg; alanine 490 mg; arginine 861 mg; glycine 270 mg; proline 570 mg; histidine 220 mg; serine 347 mg; L-glutamic acid 576 mg; L-aspartic acid 370 mg; taurine 50 mg. Electrolytes (mEq/Liter): Acetate 32.5. 561 mOsmol/Liter pH 5.5 (5.0 to 6.5) Specific Gravity = 1.02 Single dose container. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged. Use unit promptly when overwrap is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. Rx only 7 OTHER icumedical F WR-0544 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label"]},"tags":[{"label":"glutamic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glutamate receptor ionotropic, kainate 4","category":"target"},{"label":"GRIK4","category":"gene"},{"label":"GRM3","category":"gene"},{"label":"SLC1A1","category":"gene"},{"label":"A09AB01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Topical","category":"route"},{"label":"Gel","category":"form"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"CHILLS","source":"FDA FAERS","actionTaken":"32 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"22 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"CHEST DISCOMFORT","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"PALPITATIONS","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"19 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"19 reports"}],"commonSideEffects":[{"effect":"Metabolic acidosis","drugRate":"reported","severity":"unknown"},{"effect":"Alkalosis","drugRate":"reported","severity":"unknown"},{"effect":"Osmotic diuresis and dehydration","drugRate":"reported","severity":"unknown"},{"effect":"Rebound hypoglycemia","drugRate":"reported","severity":"unknown"},{"effect":"Hypo- and hyper-vitaminosis","drugRate":"reported","severity":"unknown"},{"effect":"Pulmonary embolism due to pulmonary vascular precipitates","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity reactions","drugRate":"reported","severity":"unknown"},{"effect":"Risk of infections","drugRate":"reported","severity":"unknown"},{"effect":"Refeeding syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Hyperglycemia or hyperosmolar hyperglycemic state","drugRate":"reported","severity":"unknown"},{"effect":"Vein damage and thrombosis","drugRate":"reported","severity":"unknown"},{"effect":"Hepatobiliary disorders","drugRate":"reported","severity":"unknown"},{"effect":"Aluminum toxicity","drugRate":"reported","severity":"unknown"},{"effect":"Parenteral Nutrition Associated Liver Disease","drugRate":"reported","severity":"unknown"},{"effect":"Electrolyte imbalance and fluid overload","drugRate":"reported","severity":"unknown"},{"effect":"Pulmonary vascular emboli","drugRate":"reported","severity":"unknown"},{"effect":"Vein thrombosis","drugRate":"reported","severity":"unknown"},{"effect":"Elevated liver function tests","drugRate":"reported","severity":"unknown"},{"effect":"Hyperammonemia","drugRate":"reported","severity":"unknown"},{"effect":"Electrolyte imbalances","drugRate":"reported","severity":"unknown"},{"effect":"Hypervolemia","drugRate":"reported","severity":"unknown"}],"contraindications":["Untreated anuria","Hepatic coma","Inborn errors of amino acid metabolism, including maple syrup urine disease and isovaleric acidemia","Hypersensitivity to one or more amino acids in the solution"],"specialPopulations":{"Pregnancy":"Limited published data with injectable amino acids solutions, including PROSOL in pregnant women are not sufficient to inform drug associated risk for adverse developmental outcomes. However, malnutrition in pregnant women is associated with adverse maternal and fetal outcomes. Parenteral nutrition should be considered if pregnant womans nutritional requirements cannot be fulfilled by oral or enteral intake. Severe malnutrition in pregnant women is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. However, the background risk in the U.S. general population of major birth defects is to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.","Geriatric use":"Clinical studies with PROSOL have not been performed to determine whether subjects aged 65 and over respond differently from other younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of other factors that might decrease the drugs efficacy in the elderly.","Paediatric use":"Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Plasma electrolyte concentrations should be closely monitored in the pediatric patients who may have impaired ability to regulate fluids and electrolytes. Increased risk of hypoglycemia/hyperglycemia: monitor serum glucose concentrations."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GLUTAMIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:26:34.641489+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:27:16.231610+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:26:40.369103+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:26:33.764225+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLUTAMIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:26:40.680143+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:26:28.657689+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:26:28.657716+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:27:10.893906+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:26:28.657720+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:26:42.753532+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1255943/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:26:41.993381+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:26:46.292072+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:26:50.265892+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA019398","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:26:28.657723+00:00"}},"allNames":"glutamate","offLabel":[],"synonyms":["glutamate","glutamic acid","L-Glutamic acid","glutaminic acid","glutaminol","glutamic acid hydrochloride","glutamic acid HCl"],"timeline":[],"aiSummary":"Glutamic Acid, a marketed nutritional support for infants and young children, holds a position in a niche but essential market segment. Its key strength lies in its mechanism of action, which involves binding to and activating glutamate receptors in the brain, aiding in the regulation of various physiological processes. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Glutamate","ecosystem":[],"mechanism":{"target":"Glutamate dehydrogenase 1, mitochondrial, Glutamate dehydrogenase 2, mitochondrial, Metabotropic glutamate receptor 6","novelty":"First-in-class","targets":[{"gene":"GRIK4","source":"DrugCentral","target":"Glutamate receptor ionotropic, kainate 4","protein":"Glutamate receptor ionotropic, kainate 4"},{"gene":"GRM3","source":"DrugCentral","target":"Metabotropic glutamate receptor 3","protein":"Metabotropic glutamate receptor 3"},{"gene":"SLC1A1","source":"DrugCentral","target":"Excitatory amino acid transporter 3","protein":"Excitatory amino acid transporter 3"},{"gene":"GRM1","source":"DrugCentral","target":"Metabotropic glutamate receptor 1","protein":"Metabotropic glutamate receptor 1"},{"gene":"GRIA3","source":"DrugCentral","target":"Glutamate receptor 3","protein":"Glutamate receptor 3"},{"gene":"GRM2","source":"DrugCentral","target":"Metabotropic glutamate receptor 2","protein":"Metabotropic glutamate receptor 2"},{"gene":"GRM5","source":"DrugCentral","target":"Metabotropic glutamate receptor 5","protein":"Metabotropic glutamate receptor 5"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"GRIK1","source":"DrugCentral","target":"Glutamate receptor ionotropic, kainate 1","protein":"Glutamate receptor ionotropic, kainate 1"},{"gene":"GRIK5","source":"DrugCentral","target":"Glutamate receptor ionotropic, kainate 5","protein":"Glutamate receptor ionotropic, kainate 5"}],"modality":"Small Molecule","drugClass":"Amino Acid [EPC]","explanation":"","oneSentence":"","technicalDetail":"Glutamate acts as an agonist at the glutamate receptor ionotropic, kainate 4 (GRIK4), a subtype of glutamate receptor that plays a critical role in excitatory neurotransmission."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1310","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GLUTAMIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLUTAMIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:46:28.317791","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T01:27:16.231901+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"betaine","drugSlug":"betaine","fdaApproval":"1996-10-25","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"citric acid","drugSlug":"citric-acid","fdaApproval":"1982-06-22","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"glutamic acid","indications":{"approved":[{"id":"glutamic-acid-nutritional-support-for-infant","name":"Nutritional Support for Infants and Young Children","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Infants (including low birth weight) and young children","pivotalTrial":null,"restrictions":[],"patientPopulation":"Infants (including low birth weight) and young children","diagnosticRequired":null,"brandNameForIndication":"Glutamate"},{"id":"glutamic-acid-prevent-nitrogen-and-weight-lo","name":"Prevent Nitrogen and Weight Loss","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Infants and young children with conditions affecting protein intake or requirements","pivotalTrial":null,"restrictions":[],"patientPopulation":"Infants and young children with conditions affecting protein intake or requirements","diagnosticRequired":null,"brandNameForIndication":"Glutamate"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"betaine","brandName":"betaine","genericName":"betaine","approvalYear":"1996","relationship":"same-class"},{"drugId":"citric-acid","brandName":"citric acid","genericName":"citric acid","approvalYear":"1982","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Prostate Adenocarcinoma","Stage IV Lung Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":24,"completionDate":"2027-02-12"},{"nctId":"NCT00109174","phase":"NA","title":"MRS Measurement of Glutamate and GABA Metabolism in Brain","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2006-09-06","conditions":["Normal Physiology"],"enrollment":200,"completionDate":"2030-03-11"},{"nctId":"NCT02535312","phase":"PHASE1,PHASE2","title":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-08","conditions":["Advanced Malignant Solid Neoplasm","Advanced Peritoneal Malignant Mesothelioma","Advanced Pleural Malignant Mesothelioma","Recurrent Peritoneal Malignant Mesothelioma","Recurrent Pleural Malignant Mesothelioma","Refractory Malignant Solid Neoplasm","Unresectable Solid Neoplasm"],"enrollment":30,"completionDate":"2026-10-15"},{"nctId":"NCT01064648","phase":"PHASE1,PHASE2","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-03-15","conditions":["Epithelioid Mesothelioma","Pleural Malignant Mesothelioma","Recurrent Malignant Mesothelioma","Sarcomatoid Mesothelioma"],"enrollment":117,"completionDate":"2026-03-19"},{"nctId":"NCT01915212","phase":"PHASE1","title":"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09-26","conditions":["Healthy Volunteers"],"enrollment":69,"completionDate":"2017-03-06"},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma"],"enrollment":660,"completionDate":"2028-12-31"},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":["Lung Non-Small Cell Carcinoma","Lung Non-Small Cell Squamous Carcinoma","Lung Non-Squamous Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8"],"enrollment":1210,"completionDate":"2027-01-31"},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":["Stage IB Lung Non-Small Cell Carcinoma AJCC v7","Stage II Lung Non-Small Cell Cancer AJCC v7","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Cancer AJCC v8"],"enrollment":8300,"completionDate":"2026-09-28"},{"nctId":"NCT05279053","phase":"","title":"Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":["Sex","Cigarette Smoking"],"enrollment":58,"completionDate":"2023-03-31"},{"nctId":"NCT07468903","phase":"NA","title":"Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-04-04","conditions":["Prostate Adenocarcinoma","Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8","Stage II Prostate Cancer AJCC v8"],"enrollment":45,"completionDate":"2032-04-04"},{"nctId":"NCT04874688","phase":"NA","title":"Child Health, Agriculture and Integrated Nutrition","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2021-04-26","conditions":["Stunting"],"enrollment":192,"completionDate":"2022-02-18"},{"nctId":"NCT07110532","phase":"PHASE1","title":"pH1N1 Blinded Challenge Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":["Influenza"],"enrollment":180,"completionDate":"2026-08-18"},{"nctId":"NCT05960578","phase":"PHASE2","title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-05-23","conditions":["Metastatic Castration-Resistant Prostate Carcinoma","Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":8,"completionDate":"2026-04-07"},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":["HIV I Infection","Tuberculosis"],"enrollment":276,"completionDate":"2027-04-05"},{"nctId":"NCT06453980","phase":"NA","title":"Multimodal Investigation of Neural Plasticity","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2024-05-13","conditions":["Mild Cognitive Impairment"],"enrollment":80,"completionDate":"2026-04-30"},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":["Prostate Carcinoma","Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8"],"enrollment":90,"completionDate":"2028-12-31"},{"nctId":"NCT02379377","phase":"PHASE1","title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-15","conditions":["Adult Hepatocellular Carcinoma","Resectable Hepatocellular Carcinoma","Cholangiocarcinoma","Benign Liver Tumor","Metastases to Liver"],"enrollment":110,"completionDate":"2027-05-31"},{"nctId":"NCT06272812","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-02-19","conditions":["Tuberculosis (TB)"],"enrollment":5500,"completionDate":"2028-03-31"},{"nctId":"NCT06575075","phase":"PHASE1,PHASE2","title":"Pilot Study of RR-HNK in OCD","status":"RECRUITING","sponsor":"Carolyn Rodriguez","startDate":"2026-01-23","conditions":["Obsessive-Compulsive Disorder"],"enrollment":45,"completionDate":"2029-11-30"},{"nctId":"NCT06632977","phase":"PHASE2","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-06","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":474,"completionDate":"2034-10-11"},{"nctId":"NCT06753474","phase":"PHASE1","title":"A/Texas Flu Challenge","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-02-04","conditions":["Influenza"],"enrollment":50,"completionDate":"2027-12"},{"nctId":"NCT05676463","phase":"PHASE2","title":"MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2022-11-16","conditions":["Prostate Adenocarcinoma","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8"],"enrollment":6,"completionDate":"2025-10-24"},{"nctId":"NCT04735172","phase":"NA","title":"Exploration of Differences in Metabolite Concentrations by 7Teslas NMR Spectroscopy in Striatum and Subthalamic Nuclei in de Novo Parkinsonian Patients and Control Subjects","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2022-04-07","conditions":["Parkinson's Disease"],"enrollment":44,"completionDate":"2029-08"},{"nctId":"NCT06273540","phase":"PHASE1","title":"Phase1, STP7 Cocaine Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Stalicla SA","startDate":"2024-04-15","conditions":["Cocaine Use Disorder"],"enrollment":21,"completionDate":"2024-10-07"},{"nctId":"NCT07432958","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations","status":"NOT_YET_RECRUITING","sponsor":"Appello Pharmaceuticals, Inc.","startDate":"2026-03-09","conditions":["Parkinson Disease"],"enrollment":150,"completionDate":"2028-01-03"},{"nctId":"NCT05018585","phase":"PHASE3","title":"A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diamyd Medical AB","startDate":"2022-05-19","conditions":["Type 1 Diabetes Mellitus"],"enrollment":330,"completionDate":"2027-12"},{"nctId":"NCT04631042","phase":"","title":"Developing Brain, Impulsivity and Compulsivity","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2022-09-30","conditions":["Typical Development","Obsessive Compulsive Disorder","Conduct Disorder","Attention Deficit Hyperactivity Disorder","Autism Spectrum Disorder"],"enrollment":1100,"completionDate":"2031-12-31"},{"nctId":"NCT03366766","phase":"PHASE2","title":"Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-12-20","conditions":["Non-Squamous Non-Small Cell Lung Carcinoma","Stage I Non-Small Cell Lung Cancer","Stage IA Non-Small Cell Lung Carcinoma","Stage IB Non-Small Cell Lung Carcinoma","Stage II Non-Small Cell Lung Cancer","Stage IIA Non-Small Cell Lung Carcinoma","Stage IIB Non-Small Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer"],"enrollment":14,"completionDate":"2023-02-08"},{"nctId":"NCT02148796","phase":"PHASE2","title":"Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2017-01-01","conditions":["Asthma","Wheezing"],"enrollment":822,"completionDate":"2026-01-30"},{"nctId":"NCT07076342","phase":"PHASE4","title":"The Role of mGluR5 in CBT-I","status":"RECRUITING","sponsor":"Stony Brook University","startDate":"2025-08-01","conditions":["Major Depressive Disorder (MDD)"],"enrollment":42,"completionDate":"2030-03-31"},{"nctId":"NCT04895735","phase":"PHASE2","title":"MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-07-23","conditions":["Metastatic Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Stage IV Major Salivary Gland Cancer AJCC v8","Adenoid Cystic Carcinoma"],"enrollment":45,"completionDate":"2028-02-28"},{"nctId":"NCT05806515","phase":"PHASE2","title":"Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-03-01","conditions":["Prostate Adenocarcinoma","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8"],"enrollment":44,"completionDate":"2031-06"},{"nctId":"NCT07184619","phase":"PHASE3","title":"Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia","status":"RECRUITING","sponsor":"Newron Pharmaceuticals SPA","startDate":"2026-01-23","conditions":["Treatment-resistant Schizophrenia"],"enrollment":400,"completionDate":"2026-09-01"},{"nctId":"NCT07219147","phase":"PHASE1","title":"177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-05","conditions":["Metastatic Castration-Resistant Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2028-07-26"},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":["Tuberculosis Infection"],"enrollment":16,"completionDate":"2026-01-16"},{"nctId":"NCT07360405","phase":"NA","title":"Dietary Intervention for Migraine Relief","status":"NOT_YET_RECRUITING","sponsor":"American University","startDate":"2026-01","conditions":["Migraine"],"enrollment":40,"completionDate":"2027-03"},{"nctId":"NCT05452889","phase":"EARLY_PHASE1","title":"PET Image in PAH Patients","status":"RECRUITING","sponsor":"Stephen Y. Chan","startDate":"2022-07-11","conditions":["Pulmonary Arterial Hypertension"],"enrollment":71,"completionDate":"2027-02"},{"nctId":"NCT06305182","phase":"PHASE2","title":"Metreleptin in Anorexia Nervosa","status":"RECRUITING","sponsor":"Gabriella Milos","startDate":"2024-05-31","conditions":["Anorexia Nervosa"],"enrollment":50,"completionDate":"2026-08-30"},{"nctId":"NCT07344415","phase":"NA","title":"Anxiety During Caries Removal Using Chemo-mechanical Versus Conventional Methods","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-12-31","conditions":["Caries Active"],"enrollment":80,"completionDate":"2026-01-31"},{"nctId":"NCT05924672","phase":"PHASE2","title":"Efficacy of Ra-223 in PSMA PET Optimally Selected Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-08-30","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Malignant Neoplasm in the Bone","Stage IVB Prostate Cancer AJCC v8"],"enrollment":2,"completionDate":"2027-03-31"},{"nctId":"NCT03065335","phase":"PHASE1","title":"Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2017-05-25","conditions":["Healthy Volunteer","Major Depressive Disorder","Depression"],"enrollment":150,"completionDate":"2028-01-01"},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":["Oligometastatic Prostate Carcinoma","Prostate Adenocarcinoma","Prostate Ductal Adenocarcinoma","Prostate Intraductal Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":194,"completionDate":"2029-02-01"},{"nctId":"NCT07194863","phase":"","title":"Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-11-01","conditions":["Essential Phospholipid in Metabolic Associated Fatty Liver Disease"],"enrollment":200,"completionDate":"2027-09-01"},{"nctId":"NCT03960177","phase":"EARLY_PHASE1","title":"Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2019-03-27","conditions":["Osteosarcoma"],"enrollment":12,"completionDate":"2026-12-31"},{"nctId":"NCT04872439","phase":"","title":"Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-04-22","conditions":["Autoimmune Gastrointestinal Dysmotility"],"enrollment":300,"completionDate":"2026-12-31"},{"nctId":"NCT03275974","phase":"PHASE1","title":"Glutamine PET Imaging Colorectal Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-27","conditions":["RAS Wild Type","Stage IV Colorectal Cancer","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer"],"enrollment":6,"completionDate":"2025-12-23"},{"nctId":"NCT02719951","phase":"PHASE1","title":"Glutaminergic Transmission in Autism : Molecular Imaging Exploration","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-04","conditions":["Autism","Fragile-X Syndrome (FXS)","Healthy Volunteers"],"enrollment":27,"completionDate":"2019-05"},{"nctId":"NCT06384222","phase":"PHASE2","title":"Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone","status":"RECRUITING","sponsor":"Ivan de Kouchkovsky, MD","startDate":"2024-12-09","conditions":["High Risk Prostate Carcinoma","Prostate Cancer"],"enrollment":32,"completionDate":"2027-09-30"},{"nctId":"NCT02727972","phase":"NA","title":"Examination of Glutamate and mGluR5 in Psychiatric Disorders","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-02-21","conditions":["Major Depressive Disorder","Post-Traumatic Stress Disorder","Bipolar Disorder"],"enrollment":180,"completionDate":"2022-01-13"},{"nctId":"NCT06899230","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007","status":"ACTIVE_NOT_RECRUITING","sponsor":"iQure Australia Pty Ltd","startDate":"2025-04-08","conditions":["Drug Resistant Epilepsy","Focal Seizure"],"enrollment":72,"completionDate":"2026-01-29"},{"nctId":"NCT00213915","phase":"PHASE4","title":"L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2004-02","conditions":["Heart Transplantation"],"enrollment":30,"completionDate":"2004-12"},{"nctId":"NCT04175431","phase":"PHASE2","title":"Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-09-30","conditions":["Prostate Adenocarcinoma"],"enrollment":100,"completionDate":"2033-07-01"},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":["Pancreatic Cancer"],"enrollment":328,"completionDate":"2026-05-31"},{"nctId":"NCT06511908","phase":"PHASE2","title":"Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","status":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2024-11-06","conditions":["Suicide","Depressive Disorder, Treatment-Resistant","Ketamine","Molecular Mechanisms of Pharmacological Action","Neurotransmitter Agents","Excitatory Amino Acid Agents","Physiological Effects of Drugs","Depressive Disorder, Major","Depressive Disorder","Depression","Mental Disorders","Mood Disorders","Behavioral Symptoms"],"enrollment":50,"completionDate":"2027-07-01"},{"nctId":"NCT04483466","phase":"PHASE3","title":"Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"George Washington University","startDate":"2023-07-18","conditions":["Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity"],"enrollment":150,"completionDate":"2027-08-30"},{"nctId":"NCT06967181","phase":"PHASE1","title":"A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"CyanVac LLC","startDate":"2025-05-14","conditions":["Mumps"],"enrollment":60,"completionDate":"2027-12"},{"nctId":"NCT06969937","phase":"PHASE2","title":"Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder","status":"RECRUITING","sponsor":"Dr. med. Marcus Herdener","startDate":"2025-06-01","conditions":["Alcohol Abuse/Dependence","Alcohol Use Disorder (AUD)","Alcoholism"],"enrollment":75,"completionDate":"2026-12"},{"nctId":"NCT07260734","phase":"","title":"AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2025-12-01","conditions":["OESOPHAGO-GASTRIC CARCINOMA","Oesophageal Adenocarcinoma","Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","Oesophageal Cancer Nos","Oesophageal Cancer","Oesophageal Junction Cancer","Breath Tests","Volatile Organic Compound"],"enrollment":6000,"completionDate":"2028-11-01"},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":["Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer"],"enrollment":218,"completionDate":"2028-12"},{"nctId":"NCT07196423","phase":"NA","title":"Early Psychosis: Investigating Cognition","status":"NOT_YET_RECRUITING","sponsor":"University of Nottingham","startDate":"2025-11-25","conditions":["First Episode Psychosis (FEP)","Psychosis"],"enrollment":106,"completionDate":"2026-08"},{"nctId":"NCT07240142","phase":"NA","title":"Neurotransmitter Levels in Children With Specific Learning Disorder","status":"COMPLETED","sponsor":"Dilara Ulger Ozbek","startDate":"2019-10-22","conditions":["Specific Learning Disability","Healthy (Controls)"],"enrollment":40,"completionDate":"2021-04-16"},{"nctId":"NCT06052787","phase":"PHASE3","title":"Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-09-01","conditions":["Traumatic Brain Injury"],"enrollment":150,"completionDate":"2025-08-01"},{"nctId":"NCT06903741","phase":"PHASE4","title":"New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye","status":"RECRUITING","sponsor":"Laboratoires Thea","startDate":"2025-10-21","conditions":["Dry Eye Disease (DED)"],"enrollment":30,"completionDate":"2026-06"},{"nctId":"NCT07115563","phase":"NA","title":"Daily Amino Acid Supplementation for People With Parkinson's Disease","status":"RECRUITING","sponsor":"Cristina Colon-Semenza","startDate":"2025-10-31","conditions":["Parkinson Disease (PD)"],"enrollment":30,"completionDate":"2027-11"},{"nctId":"NCT03228537","phase":"PHASE1","title":"Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-16","conditions":["Biphasic Mesothelioma","Epithelioid Mesothelioma","Stage I Pleural Malignant Mesothelioma AJCC v7","Stage IA Pleural Malignant Mesothelioma AJCC v7","Stage IB Pleural Malignant Mesothelioma AJCC v7","Stage II Pleural Malignant Mesothelioma AJCC v7","Stage III Pleural Malignant Mesothelioma AJCC v7"],"enrollment":28,"completionDate":"2026-09-18"},{"nctId":"NCT04821284","phase":"PHASE1,PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":["Locally Advanced Pancreatic Ductal Adenocarcinoma","Metastatic Pancreatic Ductal Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Ductal Adenocarcinoma"],"enrollment":120,"completionDate":"2026-02-28"},{"nctId":"NCT02286817","phase":"PHASE1","title":"Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Aevi Genomic Medicine, LLC, a Cerecor company","startDate":"2015-01","conditions":["Attention-deficit Hyperactivity Disorder (ADHD)"],"enrollment":30,"completionDate":"2016-03"},{"nctId":"NCT06524310","phase":"NA","title":"Effects of rTMS on Cognitive Functions and Behavior in Individuals With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"King Saud University","startDate":"2024-07-20","conditions":["Autism Spectrum Disorder"],"enrollment":35,"completionDate":"2025-09-30"},{"nctId":"NCT06668571","phase":"PHASE2","title":"Intravenous Ketamine for Treatment-Resistant Depression","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-10","conditions":["Depressive Disorder, Treatment-Resistant","Treatment Resistant Depression (TRD)"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT05203965","phase":"EARLY_PHASE1","title":"Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-17","conditions":["Familial Alcoholism Vulnerability"],"enrollment":80,"completionDate":"2026-07-31"},{"nctId":"NCT00862017","phase":"NA","title":"Effect of Monosodium Glutamate Supplementation on Gastric Emptying and Postprandial Nitrogen Kinetics","status":"COMPLETED","sponsor":"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement","startDate":"2008-04","conditions":["Healthy"],"enrollment":13,"completionDate":""},{"nctId":"NCT05400733","phase":"NA","title":"Prandial Metabolic Phenotype in Adults","status":"RECRUITING","sponsor":"Texas A&M University","startDate":"2022-06-24","conditions":["Protein Metabolism"],"enrollment":50,"completionDate":"2026-09"},{"nctId":"NCT02733120","phase":"NA","title":"Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2015-12-03","conditions":["Autism Spectrum Disorder"],"enrollment":40,"completionDate":"2017-10-30"},{"nctId":"NCT07007702","phase":"","title":"Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2025-01-27","conditions":["Dry Eye Disease (DED)"],"enrollment":30,"completionDate":"2025-06-30"},{"nctId":"NCT07179237","phase":"PHASE2","title":"Efficacy of Carminal in Helicobacter Pylori Gastritis","status":"RECRUITING","sponsor":"Catalysis SL","startDate":"2025-08-04","conditions":["H Pylori Gastritis","H Pylori Infection","H Pylori Eradication","Gastritis Associated With Helicobacter Pylori","Gastric Mucosal Lesion"],"enrollment":80,"completionDate":"2026-10-05"},{"nctId":"NCT05733351","phase":"PHASE1","title":"Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-08-03","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":4,"completionDate":"2025-06-12"},{"nctId":"NCT05438563","phase":"NA","title":"MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-06","conditions":["Prostate Carcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8"],"enrollment":100,"completionDate":"2027-03-07"},{"nctId":"NCT06236048","phase":"","title":"Energetics and Glutamate in Schizophrenia","status":"RECRUITING","sponsor":"King's College London","startDate":"2024-03-04","conditions":["Schizophrenia"],"enrollment":75,"completionDate":"2028-12-01"},{"nctId":"NCT05603312","phase":"PHASE1,PHASE2","title":"A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants","status":"COMPLETED","sponsor":"MeiraGTx, LLC","startDate":"2022-10-05","conditions":["Parkinson's Disease"],"enrollment":14,"completionDate":"2024-09-06"},{"nctId":"NCT06956157","phase":"PHASE4","title":"NAC for Treatment-Resistant OCD and Other Related Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-06-22","conditions":["Obsessive Compulsive Disorder (OCD)"],"enrollment":90,"completionDate":"2025-11-13"},{"nctId":"NCT05834296","phase":"PHASE1,PHASE2","title":"Study in Subjects With Mild-to-Moderate Alzheimer's Dementia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alzamend Neuro, Inc.","startDate":"2023-07-05","conditions":["Alzheimer Disease"],"enrollment":30,"completionDate":"2028-03-03"},{"nctId":"NCT04978454","phase":"PHASE1","title":"Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-19","conditions":["Influenza"],"enrollment":60,"completionDate":"2022-09-22"},{"nctId":"NCT02967640","phase":"PHASE2,PHASE3","title":"Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2018-05-30","conditions":["Rotator Cuff Tendinitis","Chronic Pain"],"enrollment":14,"completionDate":"2024-12-30"},{"nctId":"NCT05664763","phase":"EARLY_PHASE1","title":"Understanding Effects of Cannabis Use and Abstinence on Neural Glutamate Homeostasis","status":"TERMINATED","sponsor":"Yale University","startDate":"2023-03-01","conditions":["Cannabis Use Disorder"],"enrollment":6,"completionDate":"2024-07-03"},{"nctId":"NCT05894343","phase":"PHASE1,PHASE2","title":"Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"MeiraGTx, LLC","startDate":"2023-05-19","conditions":["Parkinson's Disease"],"enrollment":13,"completionDate":"2029-10"},{"nctId":"NCT03330197","phase":"PHASE1,PHASE2","title":"A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG","status":"TERMINATED","sponsor":"Alaunos Therapeutics","startDate":"2017-09-26","conditions":["Pediatric Brain Tumor","Diffuse Intrinsic Pontine Glioma"],"enrollment":6,"completionDate":"2021-09-10"},{"nctId":"NCT07087080","phase":"NA","title":"Plasma Metabolomics as a Tool to Distinguish PET-positive Malignant From PET-positive Benign Nodules","status":"RECRUITING","sponsor":"Hasselt University","startDate":"2022-03-02","conditions":["Solitary Pulmonary Nodules","Lung Cancer"],"enrollment":350,"completionDate":"2027-11-01"},{"nctId":"NCT05756621","phase":"","title":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2022-01-15","conditions":["Status Epilepticus","Cardiac Arrest"],"enrollment":80,"completionDate":"2025-09-30"},{"nctId":"NCT06584448","phase":"NA","title":"Drinking, Acetate, and Stress","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-11-06","conditions":["Alcohol Use Disorder","Alcohol Use, Unspecified","Heavy Drinker","Alcohol Use Disorder, Moderate, in Sustained Remission"],"enrollment":50,"completionDate":"2030-01"},{"nctId":"NCT04350567","phase":"NA","title":"Sleep/Wake Cycle and Depression: An Imaging and Treatment Study","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2020-09-01","conditions":["Depression; Major Depressive Disorder"],"enrollment":61,"completionDate":"2025-05-31"},{"nctId":"NCT07067606","phase":"","title":"Role of Musculoskeletal Ultrasound for Early Detection of Synovitis in SLE Patient and Its Correlation With Disease Activity and Neutrophil-to-C3 Ratio.","status":"NOT_YET_RECRUITING","sponsor":"Mervat Sayed Kamal Sayed","startDate":"2025-10-30","conditions":["Musckloskeletal US"],"enrollment":90,"completionDate":"2027-12-30"},{"nctId":"NCT06800274","phase":"PHASE4","title":"Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction","status":"COMPLETED","sponsor":"Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona","startDate":"2023-04-21","conditions":["Allergic Conjunctivitis","Dry Eye Disease (DED)"],"enrollment":134,"completionDate":"2024-03-28"},{"nctId":"NCT05064319","phase":"PHASE2","title":"Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-02-24","conditions":["Bipolar Disorder","Cannabis Use","Schizoaffective Disorder, Bipolar Type","Bipolar I Disorder","Bipolar II Disorder","Cannabis Use Disorder, Mild","Cannabis Use Disorder, Moderate","Cannabis Use Disorder, Severe"],"enrollment":68,"completionDate":"2026-06-30"},{"nctId":"NCT06401707","phase":"PHASE2","title":"PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-05-20","conditions":["Heart Arrest","Seizures","Status Epilepticus"],"enrollment":52,"completionDate":"2026-10-20"},{"nctId":"NCT03573349","phase":"EARLY_PHASE1","title":"Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-01-03","conditions":["Major Depressive Disorder","Treatment Resistant Depression","Bipolar Depression"],"enrollment":18,"completionDate":"2026-12"},{"nctId":"NCT03898297","phase":"","title":"Imaging mGluR5 and Synaptic Density in Psychiatric Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2017-01-11","conditions":["Major Depressive Disorder","Bipolar Disorder","Healthy"],"enrollment":120,"completionDate":"2026-04"},{"nctId":"NCT04785521","phase":"","title":"Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2020-07-01","conditions":["Brain Metastases, Adult"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT05775458","phase":"","title":"Glutamate Excitotoxicity and Its Role in Glioblastoma Biology","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2020-06-01","conditions":["Brain Tumor, Primary"],"enrollment":50,"completionDate":"2029-09-30"},{"nctId":"NCT04821271","phase":"PHASE2","title":"Antidepressant Effects of TS-161 in Treatment-Resistant Depression","status":"TERMINATED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2021-06-10","conditions":["Major Depressive Disorder","Treatment-Resistant Depression","Depression"],"enrollment":11,"completionDate":"2024-05-23"},{"nctId":"NCT04262479","phase":"PHASE2","title":"Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2020-03-02","conditions":["Latent Autoimmune Diabetes in Adults"],"enrollment":14,"completionDate":"2022-05-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Gel, Injection, Solution","formulations":[{"form":"GEL","route":"TOPICAL","productName":"Women Secret Care"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Kabiven"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Perikabiven"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Clinisol"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Premasol - sulfite-free (Amino Acid)"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn II"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn-PF"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ProSol"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Plenamine"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"TrophAmine"}]},"crossReferences":{"MMSL":"4788","NDDF":"001113","UNII":"3KX376GY7L","CHEBI":"CHEBI:16015","VANDF":"4018681","INN_ID":"66","RXNORM":"25916","UMLSCUI":"C0061472","chemblId":"CHEMBL1255943","ChEMBL_ID":"CHEMBL76232","KEGG_DRUG":"D00007","DRUGBANK_ID":"DB00142","PDB_CHEM_ID":" GLU","PUBCHEM_CID":"33032","SNOMEDCT_US":"38909000","IUPHAR_LIGAND_ID":"1369","SECONDARY_CAS_RN":"138-15-8","MESH_DESCRIPTOR_UI":"D018698"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":28935,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A09AB01","allCodes":["A09AB01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 27","pmid":"41905693","title":"Supplementation of glucomannans ameliorate high-fat diet-induced cognitive impairment via a gut microbiota-metabolite-glutamatergic synapse axis.","journal":"International journal of biological macromolecules"},{"date":"2026 Mar 27","pmid":"41905412","title":"Islet autoantibody profiles at diagnosis of childhood type 1 Diabetes: Age-Dependent heterogeneity and clinical implications.","journal":"Diabetes research and clinical practice"},{"date":"2026 Mar 26","pmid":"41903387","title":"Instrument-free quantitative colorimetric analysis using adsorption-band length in a packed silica gel column.","journal":"Talanta"},{"date":"2026 Apr","pmid":"41902580","title":"\"Steak Dry Aging\": An Innovative Approach to Producing High-Yield, High-Quality Dry-Aged Beef.","journal":"Journal of food science"},{"date":"2026 Mar 11","pmid":"41900040","title":"Chemical and Rheological Modifications of White Sorghum Flour by Physical Treatments with Possible Implications for Health.","journal":"Molecules (Basel, Switzerland)"}],"combinationProducts":[{"brandName":"Aminosyn II","ingredients":"alanine + arginine + aspartic acid + glutamic acid + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + proline + serine + threonine + tryptophan + valine"},{"brandName":"Aminosyn-PF","ingredients":"alanine + arginine + aspartic acid + glutamic acid + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + proline + serine + taurine + threonine + tryptophan + tyrosine + valine"},{"brandName":"Kabiven","ingredients":"alanine + arginine + aspartic acid + calcium chloride + glucose + glutamic acid + glycine + histidine + isoleucine + leucine + lysine + magnesium sulfate + methionine + phenylalanine + potassium chloride + proline + serine + sodium acetate + sodium glycerophosphate + threonine + tryptophan + tyrosine + valine"},{"brandName":"Perikabiven","ingredients":"alanine + arginine + aspartic acid + calcium chloride + glucose + glutamic acid + glycine + histidine + isoleucine + leucine + lysine + magnesium sulfate + methionine + phenylalanine + potassium chloride + proline + serine + sodium acetate + sodium glycerophosphate + threonine + tryptophan + tyrosine + valine"},{"brandName":"ProSol","ingredients":"alanine + arginine + aspartic acid + glutamic acid + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + proline + serine + threonine + tryptophan + tyrosine + valine"},{"brandName":"TrophAmine","ingredients":"alanine + arginine + aspartic acid + cysteine + glutamic acid + glycine + histidine + isoleucine + leucine + lysine acetate + methionine + phenylalanine + proline + serine + taurine + threonine + tryptophan + tyrosine + valine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-08-17T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA019398"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-09-07T00:00:00.000Z","mah":"B BRAUN","brand_name_local":null,"application_number":"NDA019018"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-07-11T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA020015"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-02-28T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"ANDA020512"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-04-12T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"NDA200656"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T01:27:16.231901+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}